Recent insights into viral infections as a trigger and accelerator in alzheimer's disease

被引：12

作者：

De Vlieger, Lize

Vandenbroucke, Roosmarijn E. ^{[1
]}

Van Hoecke, Lien

机构：

[1] VIB Ctr Inflammat Res, Barriers Inflammat Lab, Ghent, Belgium

来源：

DRUG DISCOVERY TODAY | 2022年 / 27卷 / 11期

关键词：

Alzheimer's disease; Viral infection theory; Severe acute respiratory syndrome coronavirus 2; SARS-CoV-2; Herpes simplex virus; HSV; SIMPLEX-VIRUS TYPE-1; HIV-TAT PROTEIN; SYSTEMIC INFLAMMATION; TRANSGENIC MICE; AMYLOID-BETA; BRAIN COMMUNICATION; NLRP3; INFLAMMASOME; COGNITIVE FUNCTION; MOUSE MODEL; RISK;

D O I：

10.1016/j.drudis.2022.103340

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which only symptomatic medication is available, except for the recently FDA-approved aducanumab. This lack of effective treatment urges us to investigate alternative paths that might contribute to disease development. In light of the recent SARS-CoV-2 pandemic and the disturbing neurological complications seen in some patients, it is desirable to (re)investigate the viability of the viral infection theory claiming that a microbe could affect AD initiation and/or progression. Here, we review the most important evidence for this theory with a special focus on two viruses, namely HSV-1 and SARS-CoV-2. Moreover, we discuss the possible involvement of extracellular vesicles (EVs). This overview will contribute to a more rational approach of potential treatment strategies for AD patients.

引用

页数：15

共 168 条

[1] Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses [J].